Grass pollen-derived allergy immunotherapeutic - ASIT biotech

Drug Profile

Grass pollen-derived allergy immunotherapeutic - ASIT biotech

Alternative Names: ABT-011; gp-ASIT+™; gpASIT+

Latest Information Update: 20 Sep 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator BioTech Tools
  • Developer ASIT biotech; BioTech Tools
  • Class Allergens; Allergy immunotherapies; Antiallergics; Peptides; Plant allergy immunotherapies
  • Mechanism of Action Immunosuppressants; T lymphocyte modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Allergic rhinoconjunctivitis

Most Recent Events

  • 30 Aug 2018 Phase-III clinical trials in Allergic rhinoconjunctivitis in Hungary (SC) (EudraCT2017-002911-33)
  • 14 Dec 2017 Efficacy data from a phase III trial in Allergic rhinoconjunctivitis released by ASIT biotech
  • 08 Dec 2017 ASIT biotech plans the phase III ABT-011 trial for Allergic rhinoconjunctivitis in Germany in the first half of 2019
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top